AstraZeneca’s Forxiga recommended for marketing authorization in EU

This article was originally published here

The CHMP’s positive opinion for the marketing authorization of Forxiga is for use as an oral adjunct treatment to insulin in adults with T1D. Forxiga, which is a

The post AstraZeneca’s Forxiga recommended for marketing authorization in EU appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply